Three join Pharmalink board
Pharmalink of Sweden has strengthened its board of directors with the addition of pharmaceutical and biotechnology advisors, Anders Wiklund and Jens Kristensen.
In addition, Lennart Hansson, director of lifesciences at Industrifonden joins as the Industrifonden representative. Dr Hansson replaces retiring board member Professor Joergen Loenngren. Industrifonden is an independent foundation established by the Swedish state in 1979 and an early investor in Pharmalink, holding a 15% stake.
Wiklund serves on the board of QuatRx, Gyros, and EffRx, where he is also president. He replaces retiring non-executive board member Anders Loenner.
Kristensen is vp of clinical development at KaroBio, a Swedish drug development company.